🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  2. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  3. Study of GS-0151 in Participants With Rheumatoid Arthritis

    Gilead Sciences Pty Limited

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  4. Study of GS-5319 in Adults With Solid Tumors

    Gilead Sciences Pty Limited

    Advanced solid tumors

    phase 1 other active

    1 trial

  5. Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Janssen-Cilag International N.V.

    Acute myeloid leukemia or Myelodysplastic syndrome

    phase 1 other active

    1 trial

  6. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  7. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  8. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  9. Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  10. Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  11. Study of U3-1402 in subjects with non-small cell lung cancer

    Daiichi Sankyo

    METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

    phase 1 other active

    1 trial

  12. Study of diclofenac skin reservoir formation and emptying after Voltaren Emulgel 2.32% application in healthy participants

    HALEON AUSTRALIA PTY LTD

    For the local, symptomatic treatment of pain in acute bruises, strains, or sprains due to blunt trauma, e.g., sports and accident injuries

    phase 1 other active

    1 trial

  13. Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

    Genmab A/S

    Advanced solid tumors

    phase 1 other active

    1 trial

  14. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  15. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  16. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  17. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    AbbVie Deutschland GmbH & Co. KG

    Select B-Cell malignancies.

    phase 1 other active

    1 trial

  18. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  19. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  20. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

    IONIS PHARMACEUTICALS INC

    Multiple System Atrophy

    phase 1 other active

    1 trial

  21. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  22. Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.

    The George Institute

    Idiopathic Pulmonary Fibrosis

    phase 1 other active

    1 trial

  23. Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

    Hutchmed Europe B.V.

    Primary immune thrombocytopenia (ITP)

    phase 1 other active

    1 trial

  24. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources